
Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026
<a href="https://news.google.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?oc=5" target="_blank">Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026</a>&nbsp;&nbsp;<font color="#6f6f6f">GlobeNewswire</font>
